Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
NCT ID: NCT03568929
Last Updated: 2021-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
257 participants
OBSERVATIONAL
2018-05-25
2021-10-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Idelalisib
Participants who have been or are currently being treated with 100 or 150 mg of idelalisib
Idelalisib
Tablets administered according to the product information and treatment guidelines in routine clinical practice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Idelalisib
Tablets administered according to the product information and treatment guidelines in routine clinical practice
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ziekenhuis Netwerk Antwerpen Stuivenberg Hospital
Antwerp, , Belgium
Centre Hospitalier Universitaire d'Amiens (CHU d'Amiens) - Hopital Nord
Amiens, , France
Centre Hospitalier Bourg-en-Bresse Fleyriat
Bourg-en-Bresse, , France
Centre Hospitalier de Cannes
Cannes, , France
Hôpital Privé Sévigné
Cesson-Sévigné, , France
Centre Hospitalier Chalon sur Saône William Morey
Chalon-sur-Saône, , France
Centre Hospitalier Universitaire Estaing
Clermont-Ferrand, , France
CHU de Dijon
Dijon, , France
Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard
Grenoble, , France
Clinique Victor Hugo
Le Mans, , France
Centre Hospitalier Le Mans
Le Mans, , France
Centre Hospitalier de Lens
Lens, , France
Hôpital de la Conception
Marseille, , France
Centre Hospitalier Régional d'Orléans
Orléans, , France
Centre hospitalier de Perigueux
Pessac, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Centre Hospitalier Universitaire de Poitiers
Poitiers, , France
Hopital Bretonneau, Centre Henri Kaplan
Tours, , France
Klinikum Frankfurt Hochst
Frankfurt, , Germany
Universitätsmedizin Göttingen
Göttingen, , Germany
Klinikum Südstadt Rostock
Rostock, , Germany
Gemeinschaftspraxis für Hämatologie und Onkologie Westerstede
Westerstede, , Germany
University General Hospital of Alexandroupolis
Alexandroupoli, , Greece
Athens Medical Center-Psychikon branch
Athens, , Greece
Henry Dunant Hospital
Athens, , Greece
University General Hospital of Patras
Pátrai, , Greece
AHEPA University General Hospital of Thessaloniki
Thessaloniki, , Greece
Saint James's Hospital
Dublin, , Ireland
Mater Misericordiae University Hospital
Dublin, , Ireland
Midland Regional Hospital - Mullingar
Mullingar, , Ireland
Ospedali Riuniti di Ancona, Clinica Ematologica
Ancona, , Italy
Ospedale Mazzoni
Ascoli Piceno, , Italy
Azienda Ospedaliera Policlinico di Bari
Bari, , Italy
Monsignor Raffaele Dimiccoli Hospital
Barletta, , Italy
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, , Italy
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi
Catania, , Italy
Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele
Catania, , Italy
Ospedale di Civitanova Marche
Civitanova Marche, , Italy
Azienda Ospedaliero - Universitaria Careggi
Florence, , Italy
Presidio Ospedaliero di Livorno
Livorno, , Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, , Italy
Fondazione IRCCS Cà Grande Ospedale Maggiore Policlinico
Milan, , Italy
Istituto Scientifico Universitario San Raffaele
Milan, , Italy
Azienda Ospedaliera Universitaria Maggiore Della Carita di Novara
Novara, , Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, , Italy
Azienda Ospedaliera di Perugia
Perugia, , Italy
Azienda Ospedaliera Ospedali Riuniti Marche Nord
Pesaro, , Italy
Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto
Piacenza, , Italy
Azienda Unita Sanitaria Locale di Ravenna
Ravenna, , Italy
Arcispedale Santa Maria Nuova
Reggio Emilia, , Italy
IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture
Rionero in Vulture, , Italy
Universita degli Studi di Roma La Sapienza
Roma, , Italy
Istituti di Ricovero e Cura A Carattere Scientifico - Istituti Fisioterapici Ospitalieri
Roma, , Italy
Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, , Italy
Azienda Ospedaliera Universitaria Senese-L'ospedale Santa Maria alle Scotte
Siena, , Italy
Ospedale San Bortolo di Vicenza
Vicenza, , Italy
Instituto Português de Oncologia Francisco Gentil, Centro Regional de Lisboa SA
Lisbon, , Portugal
Fundació Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain
Hospital General Universitario de Alicante
Alicante, , Spain
Hospital Universitari Germans Trias i Pujol
Badalona, , Spain
Hospital Universitari Mútua Terrassa
Barcelona, , Spain
Hospital Universitario de Burgos
Burgos, , Spain
Hospital De Cabuenes
Gijón, , Spain
Hospital Universitario Donostia
Gipuzkoa, , Spain
Institut Català d'Oncologia
L'Hospitalet de Llobregat, , Spain
Hospital Universitario Severo Ochoa
Leganés, , Spain
Hospital General Universitario Gregorio Maranon
Madrid, , Spain
Hospital San Pedro de Alcantara
Madrid, , Spain
Hospital Universitario Infanta Leonor
Madrid, , Spain
Hospital Universitario Ramon Y Cajal
Madrid, , Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Universitario Rey Juan Carlos
Móstoles, , Spain
Hospital General Universitario Morales Meseguer
Murcia, , Spain
Hospital Universitario Virgen de la Arrixaca
Murcia, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Hospital Universitario Son Dureta
Palma de Mallorca, , Spain
Clínica Universidad de Navarra
Pamplona, , Spain
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital Universitario de Canarias
Santa Cruz de Tenerife, , Spain
Hospital Universitari Arnau De Vilanova (Huav)
Valencia, , Spain
Hospital Clinico Universitario Lozano Blesa
Zaragoza, , Spain
Hospital de Día Quirónsalud Zaragoza
Zaragoza, , Spain
Karolinska Universitetssjukhuset
Stockholm, , Sweden
Velindre NHS Trust
Cardiff, , United Kingdom
St George's Healthcare NHS Trust
London, , United Kingdom
South Tees Hospitals Nhs Foundation Trust
Middlesbrough, , United Kingdom
Abertawe Bro Morgannwg University Health Board
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Gilead Clinical Trials Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUPAS19618
Identifier Type: OTHER
Identifier Source: secondary_id
GS-EU-313-4172
Identifier Type: -
Identifier Source: org_study_id